AMIVAS is a US, Australian and European joint-venture pharmaceutical company that develops, manufactures and distributes Artesunate for the emergency treatment of severe malaria. With offices in the United States, Australia and Ireland, it manufactures in North America and works with regional partners to supply hospitals and patients across multiple markets. Its first commercial product received U.S. FDA approval on May 26, 2020, after quinidine gluconate was discontinued in 2019.
U.S. Food and Drug Administration (FDA) approval for Artesunate
registration
Medicines and Healthcare products Regulatory Agency (MHRA) authorization for Artesunate
registration
European Medicines Agency (EMA) registration for Artesunate
registration